5 Most Heavily Traded Biotech Stocks: Gilead Sciences, Sequenom, Arena, MannKind, VIVUS

Gilead Sciences, Inc.(NASDAQ:GILD) added more than 2% on Tuesday to set new high after providing  more clinical trial data for the new pill, called TAF. In other news, the USA-based AIDS Healthcare Foundation (AHF) demanded the Food and Drug Administration to remove GILD’s HIV prevention pill Truvada for use by women citing insufficient data demonstrating the drug’s safety and efficacy.

Significantly, its latest price of $45.02 is at a premium of 37.82% to its 200-day moving average price of $36.06. Its 52-week range has been $22.40 to $45.58 and it is trading at a premium of 100.98% to its 52-week low.

Sequenom, Inc.(NASDAQ:SQNM) traded down on a volume of 8.35 million, higher than its standard daily volume. Shares have dropped 3.52% to $4.39 after Wedbush reiterated its neutral rating on the stock. Over the last twelve months, the stock has gained0.69% and faced a worst price of $2.65 on Aug 02, 2012. The stock has moved down across its 50-day moving average of $4.34.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) moved up +4.27% to close at $8.54, rebounding after its weak quarterly report. The most recent price of ARNA is now at a discount of 36.74% to the 12-month high of $13.50 hit on Jun 27, 2012. The last price is at a premium of 402.35% to the 52-week low of $1.70 suffered on Mar 07, 2012.

MannKind Corporation(NASDAQ:MNKD) saw its price gain on above-normal volume, as 5.49 million shares changed hands when compared with its average daily volume of 2.66 million shares.

The stock was up +2.63% to $2.73 after the company presented at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley in Boston, Massachusetts held on March 5, 2013. It has advanced over the last 12 months, increasing20.26% and marked new low $1.57 on May 18, 2012. At the end of recent trade, the stock has moved up across its SMA 200 of $2.39.

VIVUS, Inc.(NASDAQ:VVUS) also traded higher after its participation at Cowen Health Care Conference. In the last trading session, VVUS was up on high volume, trading at a volume of 5.48 million versus its average daily volume of 3.16 million shares. At $10.44, the stock has gained momentum as shares are down -66.55% from a peak price of $31.21 on Jul 18, 2012. The stock is trading at -16.69% of its 20-day moving average and -20.08% of its 50-day moving average.